Oral nanomedicine improves effectiveness of cancer immunotherapy

A team of researchers at the University of Michigan has reported in *Nature Nanotechnology* the development of an oral medication that enhances the ability of T cells to attack cancer cells. The study describes a drug that, when taken by mouth, releases the natural “brakes” on the immune system, thereby boosting the cytotoxic activity of T cells against tumors.

Immune‑checkpoint blockade therapies have revolutionized cancer treatment by allowing the body’s own immune cells to recognize and destroy malignant cells. However, response rates remain low for many patients, limiting the overall effectiveness of these drugs. The new oral formulation aims to overcome this limitation by amplifying T‑cell function, potentially widening the range of patients who can benefit from checkpoint inhibition.

If subsequent clinical trials confirm the pre‑clinical findings, the drug could offer a more convenient and broadly effective strategy for improving outcomes in patients receiving immune‑checkpoint therapy, marking a significant step forward in the pursuit of more universally responsive cancer immunotherapies.